logo-loader

Insight Widest with the analysis. We look at the companies others don’t, giving access to the opportunities others won’t.

ANGLE’s Parsortix liquid biopsy proving to be more than just a...

The cancer detection system is “on track” for submission with the US FDA early in the fourth quarter,...

Opinion We bridge the gap between knowledge and ignorance and give you the angle that hard facts alone won’t

Research Independent research from the expert Proactive analyst team

MaxCyte Inc - MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering

Strategic Minerals

MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering

Health

MaxCyte - Pole Position in...

MaxCyte Inc (LON:MXCT) is well-positioned to leverage its proprietary flow...

Health

Open Orphan: Leveraging...

Open Orphan (ORPH) is targeting rapid scale-up and profitability in the dynamic...